Cargando…
Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast.
The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of D...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968340/ https://www.ncbi.nlm.nih.gov/pubmed/8385977 |
_version_ | 1782134718900207616 |
---|---|
author | Luqmani, Y. A. Campbell, T. Soomro, S. Shousha, S. Rio, M. C. Coombes, R. C. |
author_facet | Luqmani, Y. A. Campbell, T. Soomro, S. Shousha, S. Rio, M. C. Coombes, R. C. |
author_sort | Luqmani, Y. A. |
collection | PubMed |
description | The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of DCIS, with significant positivity found in 63-67% of cases. In 15 samples analysed, we found a good correlation between pS2 expression and presence of progesterone receptor positive cells, but not with estrogen receptor. There was only a limited degree of correspondence between the cells staining with these anti-sera. Some pS2 positive cells were also seen in normal acini in areas adjacent to cancer but much less frequently in sections of normal breast from reduction mammoplasty. Most normal areas were negative, as were cysts. In benign proliferative conditions (seen in sections with and without DCIS) such as adenosis, sclerosing adenosis, mild and florid ductal epithelial hyperplasia, significant pS2 positivity was seen in about 50% of cases. These results suggest that there is a progressive increase in pS2 from normal to benign to cancer cells and that this gene is expressed in both the invasive and pre-invasive forms of breast cancer. IMAGES: |
format | Text |
id | pubmed-1968340 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1993 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-19683402009-09-10 Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. Luqmani, Y. A. Campbell, T. Soomro, S. Shousha, S. Rio, M. C. Coombes, R. C. Br J Cancer Research Article The expression of pS2 was examined histochemically in paraffin sections taken from biopsy material from patients diagnosed with ductal carcinoma in situ (DCIS). Often intense immunoreactivity, to an anti-pS2 monoclonal antibody, was observed in comedo, solid, cribriform and micropapillary types of DCIS, with significant positivity found in 63-67% of cases. In 15 samples analysed, we found a good correlation between pS2 expression and presence of progesterone receptor positive cells, but not with estrogen receptor. There was only a limited degree of correspondence between the cells staining with these anti-sera. Some pS2 positive cells were also seen in normal acini in areas adjacent to cancer but much less frequently in sections of normal breast from reduction mammoplasty. Most normal areas were negative, as were cysts. In benign proliferative conditions (seen in sections with and without DCIS) such as adenosis, sclerosing adenosis, mild and florid ductal epithelial hyperplasia, significant pS2 positivity was seen in about 50% of cases. These results suggest that there is a progressive increase in pS2 from normal to benign to cancer cells and that this gene is expressed in both the invasive and pre-invasive forms of breast cancer. IMAGES: Nature Publishing Group 1993-04 /pmc/articles/PMC1968340/ /pubmed/8385977 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Luqmani, Y. A. Campbell, T. Soomro, S. Shousha, S. Rio, M. C. Coombes, R. C. Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. |
title | Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. |
title_full | Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. |
title_fullStr | Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. |
title_full_unstemmed | Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. |
title_short | Immunohistochemical localisation of pS2 protein in ductal carcinoma in situ and benign lesions of the breast. |
title_sort | immunohistochemical localisation of ps2 protein in ductal carcinoma in situ and benign lesions of the breast. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968340/ https://www.ncbi.nlm.nih.gov/pubmed/8385977 |
work_keys_str_mv | AT luqmaniya immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast AT campbellt immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast AT soomros immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast AT shoushas immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast AT riomc immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast AT coombesrc immunohistochemicallocalisationofps2proteininductalcarcinomainsituandbenignlesionsofthebreast |